Skip to main content
OpenTrials
Completed

NCT Number: NCT02651454

A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -

The Purpose of this trial is to investigate the efficacy and safety of Daesiho-tang and Taeeumjowi-tang on Korean obese Women with metabolic syndrome Risk factors

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Gachon University Gil Oriental Medical Hospital

Incheon, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female aged 18 to 65 years
  • Subject must included at least one or more of the following symptoms below
  • BMI of 30 kg/㎡ or more;
  • BMI between 25 and 29.9kg/㎡ with hypertension, taking medication or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit
  • BMI between 25 and 29.9kg/㎡ with non-insulin-dependent diabetes mellitus, taking medication or fasting blood glucose > 126mg/dL at the screening visit
  • BMI between 25 and 29.9kg/㎡ with hyperlipidemia, taking medication or total cholesterol ≥ 200mg/dL or Triglyceride ≥ 150mg/dL at screening visit
  • Agreed to low-calorie diet during the trial
  • Written informed consent of the trial

Exclusion criteria

  • Endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc.
  • Heart disease (heart failure, angina pectoris, myocardial infarction)
  • Cholelithiasis
  • Severe renal disability (SCr > 2.0 mg/dL)
  • Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
  • History of narrow angle glaucoma
  • History of stroke or temporary ischemic cardioplegia
  • History of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
  • Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion)
  • Use of CNS stimulant medication for weight loss
  • Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
  • history of weight loss surgery, such as bariatric surgery, etc.
  • Subjects who are judged to be inappropriate for the clinical study by the researchers
  • Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.)
  • Use of other investigational product within last 1 month
  • 10 percent reduction in body weight over 6 months
  • Decided to quit smoking over the last 3 months or have irregular smoking habits

Treatment and study plan

Daesiho-tang

Drug

Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.

Other names: DSHT, Elsion Granule

Chowiseungcheng-tang

Drug

Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.

Other names: CST

Placebo

Drug

Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.

Primary outcomes

  1. Changes from baseline in body weight

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. Changes from baseline in body fat percentage

    Time frame: baseline, 4,8,12,16 weeks

  2. Changes from baseline in fat mass

    Time frame: baseline, 4,8,12,16 weeks

  3. Changes from baseline in Waist circumference

    Time frame: baseline, 4,8,12,16 weeks

  4. Changes from baseline in Waist/hip ratio

    Time frame: baseline, 4,8,12,16 weeks

  5. Changes from baseline in Body mass index

    Time frame: baseline, 4,8,12,16 weeks

  6. Changes from baseline in Lipid profile

    Time frame: Screening visit, 12 weeks

  7. Changes from baseline in C-reactive protein (CRP)

    Time frame: Screening visit, 12 weeks

  8. Changes from baseline in blood glucose

    Time frame: Screening visit, 12 weeks

  9. Changes from baseline in abdominal visceral fat area

    Time frame: baseline, 12 weeks

  10. Korean Obesity-related Quality of Life (QoL) scale

    Time frame: baseline, 12 weeks

  11. Korean version of Eating Attitudes Test-26

    Time frame: baseline, 12 weeks

Sponsors and collaborators

Lead sponsor

Gachon University Gil Oriental Medical Hospital

Other

Collaborators

  • DongGuk University
  • Sangji University Oriental Medical Hospital, Korea

Registry information

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Jan 11, 2016
Registry last updated
Apr 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.